Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.46 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.46 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.46 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.46 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.46 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.46 |
| ▸ | RORC | P51449 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8022068 | 0.88 | ADRA1A (0.39) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11088958 | 0.87 | PSEN1 (0.41) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11826260 | 0.87 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL4430870 | 0.86 | PSEN1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL11822928 | 0.85 | MAPT (0.38) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL9055658 | 0.85 | PSEN1 (0.37) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL17542850 | 0.84 | PSEN1 (0.52) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL735539 | 0.84 | MEN1 (0.42) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL1558214 | 0.82 | RORC (0.45) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL14341345 | 0.82 | PSEN1 (0.48) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044004-B1 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC (US) | 2012-08-15 | — | — | EP | disclosed |
| EP-2253328-A1 | Cycloalkyl inhibitors of potassium channel function | Bristol-Myers Squibb Company (US) | 2010-11-24 | — | — | EP | disclosed |
| WO-2007145835-A2 | BENZAMIDE DERIVATIVES AS MODULATORS OF 11BETA-HSD1 FOR TREATING DIABETES AND OBESITY | AMGEN INC. (US) | 2007-12-21 | — | — | WO | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | BRISTOL-MYERS SQUIBB COMPANY | 2007-06-21 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-7202253-B2 | Cycloalkyl inhibitors of potassium channel function | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-04-10 | — | — | US | disclosed |
| US-5972979-A | Tricyclic spiro compounds as 5HT1D receptor antagonists | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5952325-A | Tricyclic spiro compounds process for their preparation and their use of 5HT1D receptor antagonists | SMITHKLINE BEECHAM PLC (GB) | 1999-09-14 | — | — | US | disclosed |
| EP-0862565-A1 | TRICYCLIC SPIRO COMPOUNDS AS 5HT 1D? RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1998-09-09 | — | — | EP | disclosed |
| EP-0787133-A1 | TRICYCLIC SPIRO COMPOUNDS PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-08-06 | — | — | EP | disclosed |
| WO-1997019070-A1 | TRICYCLIC SPIRO COMPOUNDS AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1997-05-29 | — | — | WO | disclosed |
| WO-1996011934-A1 | TRICYCLIC SPIRO COMPOUNDS PROCESS FOR THEIR PREPARATION AND THEIR USE AS 5HT1D RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 1996-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142333-A1 | CYCLOALKYL INHIBITORS OF POTASSIUM CHANNEL FUNCTION | KCNJ2, KCNN3, KCNQ5 | PSEN1 891/4885PSEN2 1360/4885APH1B 1660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.